OXALIEVA 100 mg contains Oxaliplatin, a third-generation platinum-based chemotherapy (anticancer) drug. It forms DNA cross-links, inhibiting DNA synthesis and transcription, which leads to cancer cell death. Oxaliplatin is particularly effective in colorectal cancer and has lower nephrotoxicity and ototoxicity compared to cisplatin.

Oxaliplatin Injection is used in the treatment of:

        • Colorectal cancer (adjuvant and metastatic)

        • Gastric (stomach) cancer

        • Pancreatic cancer

        • Ovarian cancer (off-label, in combination regimens)

 Commonly used in the FOLFOX regimen (with 5-Fluorouracil and Leucovorin)

Common side effects:

       • Peripheral neuropathy (tingling, numbness in hands/feet)

       • Acute cold-induced dysesthesia (throat tightness, jaw spasm)

       • Nausea and vomiting

       • Diarrhea

       • Fatigue

• Myelosuppression

Serious side effects:

       • Severe or persistent peripheral neuropathy

       • Hypersensitivity reactions

       • Severe diarrhea and dehydration

       • Liver enzyme abnormalities

Avoid cold drinks and cold exposure during and after infusion to reduce neuropathy.

Dose is based on body surface area (BSA) and chemotherapy protocol.

Common dosing regimens:

      • 85 mg/m² IV infusion every 2 weeks

      • 130 mg/m² IV infusion every 3 weeks

 Administered as a slow intravenous infusion under oncologist supervision.